KIORA PHARMACEUTICALS, INC. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
KIORA PHARMACEUTICALS, INC. (KPRX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $4.62 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $4.62M.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2024-09-30 was $2.01M, a 5.44% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $4.62M, a 130.28% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $2.01M, a 5.44% increase from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $1.90M.
- KIORA PHARMACEUTICALS, INC. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.62M derived: sum of 2 quarters · filed 2026-03-25 | $4.62M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.01M derived: sum of 2 quarters · filed 2026-03-25 | $2.01M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $2.01M 10-Q · filed 2025-11-07 | $2.01M 10-Q · filed 2025-11-07 | |||
| 2024-08-31 | $2.00M 10-K · filed 2026-03-25 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $1.90M derived: sum of 2 quarters · filed 2025-03-25 | $1.90M 10-K · filed 2025-03-25 | ||
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-08 | $1.90M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |